Discussing the Role of Tivozanib in the Third-Line of RCC Treatment

EP: 1.Tivozanib Shows Efficacy and Safety in Heavily Pretreated ccRCC

EP: 2.Discussing Tolerability of Tivozanib as Third-Line Therapy for mRCC

EP: 3.Reviewing Efficacy and Tolerability in TIVO-3 Trial of Tivozanib for RCC

EP: 4.Second-Line Considerations After Immune Toxicity From Prior RCC Therapy

EP: 5.Factors Favoring Tivozanib as Third-Line Therapy for Advanced RCC

EP: 6.Lenvatinib/Everolimus Vs Tivozanib Evaluated for Later-Line RCC

EP: 7.Factors for Selecting Later-Line Therapies in Advanced RCC

Now Viewing

EP: 8.Discussing the Role of Tivozanib in the Third-Line of RCC Treatment

EP: 9.Use of Immunotherapy Considered in Later Lines of RCC Therapy

EP: 10.Choosing Between Tivozanib and Lenvatinib/Everolimus in Third-Line RCC

EP: 11.Integrating Tivozanib into Treatment of Advanced RCC

EP: 12.Hammers and Participants Discuss AEs Associated with TKIs in RCC

EP: 13.Navigating Third-Line Treatment in R/R Metastatic RCC

EP: 14.Assessing Second- and Third- Line Therapies in Advanced RCC

EP: 15.Sequencing Choices from First- to Third-Line Regimens in ccRCC

EP: 16.Key Efficacy and Tolerability Factors for Later-Line Therapies in RCC

EP: 17.Peers Discuss Impressions of Tivozanib’s Role as Third-Line RCC Therapy

EP: 18.Tolerability Concerns Influence Use of Lenvatinib/Everolimus Vs Tivozanib in RCC

EP: 19.Tolerability Helps Decide Third-Line Treatment in Advanced RCC

EP: 20.Long-Term Durability Favors Tivozanib Vs Other TKI in Recurrent mRCC

EP: 21.The Field of Recurrent RCC Regimens Continues to Grow

Helen H. Moon, MD, principal investigator with the Cancer Clinical Trials Access Program in the Southern California Permanente Medical Group, research lead for melanoma, regional medical oncology lead for genitourinary cancer, and hematologist/oncologist at Kaiser Permanante Riverside Medical Center, discusses the usefulness of tivozanib (Fotivda) for patients with recurrent clear cell renal cell carcinoma (ccRCC) in the third-line setting.

The efficacy and safety data of this therapy is from the phase 3 TIVO-3 trial (NCT02627963), which randomly assigned patients who had failed 2 or 3 systemic lines of therapy to tivozanib versus sorafenib (Nexavar).

The trial showed that patients receiving tivozanib had a higher median progression-free survival of 5.6 months versus 3.9 months for patients on sorafenib (HR 0.73; 95% CI, 0.56-0.94; P = .016). Moreover, at the time of the primary analysis, the objective response rate was 18% among patients given the tyrosine kinase inhibitor (TKI) compared with 8% for patients given sorafenib.

According to Moon, this demonstrates the impact this therapy can have in the third-line setting for patients who failed several lines of therapy prior. Compared with therapies in the first line setting for patients with ccRCC, there has yet to be as effective treatments for patients experiencing recurrent disease. Now, with tivozanib showing no new safety signals—except for hypertension, which Moon explains is a class effect of TKIs— there is now another option to consider for these heavily pretreated patients.

Transcription:

0:08 | We're increasingly getting patients, when they get to the third line, having already been exposed to both TKI and immunotherapy. And so, what we have left as they enter into that place in treatment is [that] they're looking for effective treatment with increasing awareness of the adverse event profile and tivozanib really fits quite well into that space.

0:35 | There are preclinical data, [and now] certainly with the results of TIVO-3, it really indicates a highly effective therapy and a very potent blocker of the [VEGF pathway] and that compared to sorafenib, which is a representative TKI of that first generation, it is better.